/ /

  • linkedin
  • Increase Font
  • Sharebar

    10 things you may have missed at ARVO


    5. Anti-VEGF shows benefits for CNV with rare diseases

    Injections with ranibizumab (Lucentis, Genentech) were shown to be safe and effective at improving functional and anatomic status in patients with choroidal neovascularization associated with rare diseases, according to findings from the phase III MINERVA study.


    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results